Search Results
Results found for "Jan Voss"
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
.- Jan Steyaert, scientific director of the VIB-VUB Center for Structural Biology, Vlaams Instituut Biotechnologie Jan Steyaert will be presented with the Gabbay Award at Brandeis University on October 27 when he will
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Lukas Grätz , Jan Voss , and Gunnar Schulte , for their study on Class-Wide Analysis of Frizzled-Dishevelled
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics" Ross
- Dual loss of regulator of G protein signaling 2 and 5 exacerbates ventricular myocyte arrhythmias...
October 2022 Dual loss of regulator of G protein signaling 2 and 5 exacerbates ventricular myocyte arrhythmias
- N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 ...
October 2022 N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
GPCRs posses a seven-transmembrane domain architecture, which lets them transduce extracellular signals Chem Rev. 2017 Jan 11;117(1):139-155. Chem Rev. 2017 Jan 11;117(1):139-155. doi: 10.1021/acs.chemrev.6b00177 Alavi MS, Shamsizadeh A, Azhdari-Zarmehri
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis "SAN CARLOS, Calif., Jan
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "Jan
- Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
and commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan
- Fluorescence Polarization in GPCR Research
ACS Med Chem Lett. 2022 Jan 10;13(2):243-249. doi: 10.1021/acsmedchemlett.1c00598.
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
. 📝 Manuscript summary deadline: 23 Sept 2025 📄 Submission deadline: 11 Jan 2026 Submit to Volume II
- Advantages of Fluorescent Probes in GPCR Assays
Biochim Biophys Acta. 2014 Jan;1838(1 Pt A):15-33. doi: 10.1016/j.bbamem.2013.09.005.
- New role of β-arrestins in MOR signaling
Biochem Biophys Res Commun. 2023 Jan 15;640:64-72. doi: 10.1016/j.bbrc.2022.11.098.
- Hear the sounds: the role of G protein-coupled receptors in the cochlea
for the understanding of the cochlea development, hearing disorders, and the treatment for hearing loss In addition, hearing loss can be caused by mutations of certain GPCRs, such as Vlgr1, Gpr156, S1P2, and A1, A2A, and CB2 activation by agonists has protective functions on noise- or drug-induced hearing loss GPCR in the cochlea and discuss the role of GPCR in the cochlea, such as stem cell fate, PCP, hearing loss
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
I was up every night thinking about how to hire, how to lead, how to avoid the mistakes my bad bosses
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
How do we prevent lean muscle loss during weight loss?
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
It’s about finding purpose through loss, choosing academia when many peers walk away, and designing science That personal loss transforms complex receptor pharmacology into something immediate and human.
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Novo Nordisk’s amycretin showed up to 24% weight loss, CagriSema delivered 22.7% in Phase 3, and semaglutide
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
Mark: “Beth, why would someone want you as their boss?”
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
dysregulated membrane trafficking, stability and phototransduction processes that lead to progressive loss
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..
Moreover, independent of glucose control or weight loss, the anti-inflammatory actions of GLP-1RAs require
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
the so-called metabolic surgery whose beneficial effects are beyond dietary restrictions and weight loss
- Comparative study of neuropeptide signaling systems in Hemiptera
Independent secondary losses of the adipokinetic hormone/corazonin-related peptide receptor (ACP) and
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
damage to healthy cells in the process, leading to side effects that can include pain, nausea, and hair loss
- Statin-induced increase in actin polymerization modulates GPCR dynamics and compartmentalization
cholesterol-depleted cells (using statins) by fluorescence recovery after photobleaching (FRAP) and fluorescence loss
- GPR84 signaling promotes intestinal mucosal inflammation via enhancing NLRP3 inflammasome activation
pro-inflammatory properties in colonic macrophages through enhancing NLRP3 inflammasome activation, while the loss
- Lysine 101 in the CRAC Motif in Transmembrane Helix 2 Confers Cholesterol-Induced Thermal...
Our results show that a mutation in the K101 residue leads to loss in thermal stability of the serotonin1A
- Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal
Though most of these variants exhibit a loss of function, the molecular defects caused by these underlying
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic diabetes insipidus "Loss-of-function
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
efficacy depends on which cells express the receptor Side effects are tied to where agonists bind Weight-loss











